Subscribe
Casimiro PT / Shutterstock.com
22 May 2025NewsEuropeMarisa Woutersen

UK court clears the way for Amgen and Samsung to launch biosimilars

AstraZeneca subsidiary Alexion suffers setback in bid to stop rivals launching biosimilars of blood disorder drug | Ruling concerns an error in original patent application | Decision follows UPC defeat for Alexion over eculizumab patent.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
AstraZeneca unit faces class-action suit over alleged Soliris monopoly
17 April 2025   Massachusetts lawsuit claims subsidiary of UK pharma company unlawfully re-patented eculizumab, resulting in overpayments of more than $2 billion.
Americas
AstraZeneca unit draws line under Samsung dispute
5 September 2024   AstraZeneca unit and Samsung Bioepis resolve their patent dispute over a biosimilar | Settlement follows FDA approval for the generic drug in July 2024 | Agreement dismisses ongoing litigation and appeals, including a federal lawsuit and related patent reviews.
Europe
Life sciences cases at the UPC will surely rise, but is the court prepared?
18 June 2024   Signs show that an uptick of life sciences cases at the Unified Patent Court is likely, but does the court have capacity? Anna Leathley, Richard Newell & Sarah Mitchell of Carpmaels & Ransford explore.


Editor's picks

LSPN: In-house ‘chess game’ is the same, but the rules have changed
Americas
LSPN: In-house ‘chess game’ is the same, but the rules have changed
9 May 2025

Editor's picks

Americas
LSPN: In-house ‘chess game’ is the same, but the rules have changed
9 May 2025
Americas
LSPN: Counsel grapple with AI’s impact on training and critical thinking
8 May 2025
Americas
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
6 May 2025
Americas
Why US patent reform is ‘essential’ for US economic prosperity and security
29 April 2025
Europe
Meril v Edwards: Harmonisation of obviousness at the UPC and the EPO
24 April 2025
Americas
WIPR Diversity & Inclusion reveals Top 100 People in IP for 2025
24 April 2025

More on this story

Big Pharma
AstraZeneca unit faces class-action suit over alleged Soliris monopoly
17 April 2025   Massachusetts lawsuit claims subsidiary of UK pharma company unlawfully re-patented eculizumab, resulting in overpayments of more than $2 billion.
Americas
AstraZeneca unit draws line under Samsung dispute
5 September 2024   AstraZeneca unit and Samsung Bioepis resolve their patent dispute over a biosimilar | Settlement follows FDA approval for the generic drug in July 2024 | Agreement dismisses ongoing litigation and appeals, including a federal lawsuit and related patent reviews.
Europe
Life sciences cases at the UPC will surely rise, but is the court prepared?
18 June 2024   Signs show that an uptick of life sciences cases at the Unified Patent Court is likely, but does the court have capacity? Anna Leathley, Richard Newell & Sarah Mitchell of Carpmaels & Ransford explore.

More on this story

Big Pharma
AstraZeneca unit faces class-action suit over alleged Soliris monopoly
17 April 2025   Massachusetts lawsuit claims subsidiary of UK pharma company unlawfully re-patented eculizumab, resulting in overpayments of more than $2 billion.
Americas
AstraZeneca unit draws line under Samsung dispute
5 September 2024   AstraZeneca unit and Samsung Bioepis resolve their patent dispute over a biosimilar | Settlement follows FDA approval for the generic drug in July 2024 | Agreement dismisses ongoing litigation and appeals, including a federal lawsuit and related patent reviews.
Europe
Life sciences cases at the UPC will surely rise, but is the court prepared?
18 June 2024   Signs show that an uptick of life sciences cases at the Unified Patent Court is likely, but does the court have capacity? Anna Leathley, Richard Newell & Sarah Mitchell of Carpmaels & Ransford explore.

More features

As AI shakes up pharma and biotech, can patent law keep up?
SK Bioscience prevails over Pfizer in pneumococcal vaccine dispute
‘It’s going to be very different’: INTA CEO shares London meeting plans
'Scrap the billable hour': LSIPR joins INTA panel on gender diversity
Sanofi unit loses genetic disorder patent at EPO after trio of challenges
INTA confirms London as host city for Annual Meeting 2026
INTA unveils key principles on AI and IP rights at Annual Meeting
Illumina takes aim at rival in gene sequencing spat